Background. There is concern that human immunodeficiency virus (HIV) infection and the
use of highly active antiretroviral therapy lead to accelerated atherosclerosis and increased …

The chronic inflammation induced by human immunodeficiency virus (HIV) contributes to
increased risk of coronary heart disease (CHD) in HIV-infected individuals. HIV-infected …

Background Cardiovascular disease (CVD) is an increasing cause of morbidity among
persons living with human immunodeficiency virus (HIV; PLWH). We projected cumulative …

Objective Highly active antiretroviral therapy (HAART) has been associated with
dyslipidaemia; however, the roles of immune status and non‐HIV‐disease risk factors …

Abstract Purpose of Review The proportion of overweight and obese persons with HIV
(PWH) has increased since the introduction of antiretroviral therapy (ART). We aim to …

The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for
cardiovascular disease (CVD), including elevated triglyceride (TG), low high density …

Background. Obesity and lipohypertrophy are common in treated human immunodeficiency
virus (HIV) infection and contribute to morbidity and mortality among HIV-infected adults on …

Background Cardiovascular diseases (CVD) due to atherosclerosis have become one of the
major causes of death among people living with HIV (PLHIV) since effective antiretroviral …

Background: As a result of effective antiretroviral therapy HIV patients are living longer, and
their risk of cardiovascular disease (CVD) is a growing concern. It remains unknown whether …

Background and Aims: Prior cross-sectional studies have found inconsistent relationships
between body mass index (BMI) and disease progression in HIV-infected individuals …